

10/513699

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptaéal1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 AUG 10 Time limit for inactive STN sessions doubles to 40
minutes
NEWS 3 AUG 18 COMPENDEX indexing changed for the Corporate Source
(CS) field
NEWS 4 AUG 24 ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS 5 AUG 24 CA/CAPLUS enhanced with legal status information for
U.S. patents
NEWS 6 SEP 09 50 Millionth Unique Chemical Substance Recorded in
CAS REGISTRY
NEWS 7 SEP 11 WPIDS, WPINDEX, and WPIX now include Japanese FTERM
thesaurus
NEWS 8 OCT 21 Derwent World Patents Index Coverage of Indian and
Taiwanese Content Expanded
NEWS 9 OCT 21 Derwent World Patents Index enhanced with human
translated claims for Chinese Applications and
Utility Models
NEWS 10 OCT 27 Free display of legal status information in CA/CAPLUS,
USPATFULL, and USPAT2 in the month of November.
NEWS 11 NOV 23 Addition of SCAN format to selected STN databases
NEWS 12 NOV 23 Annual Reload of IFI Databases

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN customer
agreement. This agreement limits use to scientific research. Use
for software development or design, implementation of commercial
gateways, or use of CAS and STN data in the building of commercial
products is prohibited and may result in loss of user privileges
and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:55:20 ON 23 NOV 2009

<12/04/2007>

Erich Leese

10/513699

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.22

0.22

FILE 'REGISTRY' ENTERED AT 17:55:27 ON 23 NOV 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 NOV 2009 HIGHEST RN 1193309-59-9

DICTIONARY FILE UPDATES: 22 NOV 2009 HIGHEST RN 1193309-59-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10598262last.str



```

chain nodes :
12 14 15 17 18 19 20 22 23
ring nodes :
1 2 3 4 5 6 7 8 9 10 24 25 26 27 28 29
chain bonds :
7-14 7-15 8-22 8-23 9-17 9-18 10-19 10-20 12-24
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 24-25 24-29 25-26 26-27
27-28 28-29
exact/norm bonds :
5-7 6-10 7-8 7-14 7-15 8-9 8-22 8-23 9-10 9-17 9-18 10-19 10-20 12-24
24-25 24-29 25-26 26-27 27-28 28-29
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 24 :
```

G1:H,N

G2:C,H

G3:C,N

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
12:CLASS 14:CLASS 15:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 22:CLASS
23:CLASS 24:CLASS 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 32:Atom
```

L1 STRUCTURE UPLOADED

=> s ll sss

SAMPLE SEARCH INITIATED 17:56:05 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 119757 TO ITERATE

1.7% PROCESSED 2000 ITERATIONS 0 ANSWERS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 2374598 TO 2415682
 PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s ll full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 185.40 U.S. DOLLARS
 DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
 FULL SEARCH INITIATED 17:56:10 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 2402134 TO ITERATE

81.8% PROCESSED 1963985 ITERATIONS 190 ANSWERS
 83.3% PROCESSED 2000000 ITERATIONS 190 ANSWERS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.23

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 2402134 TO 2402134
 PROJECTED ANSWERS: 190 TO 273

L3 190 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	186.36	186.58

FILE 'CAPLUS' ENTERED AT 17:56:37 ON 23 NOV 2009
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching

10/513699

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Nov 2009 VOL 151 ISS 22
FILE LAST UPDATED: 22 Nov 2009 (20091122/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

CPlus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

During November, try the new LSUS format of legal status information in the CA/CPlus family databases for free! Complete details on the number of free displays and other databases participating in this offer appear in NEWS 10.

=> s l3 full
L4 20 L3

=> d ibib abs hitstr tot
THE ESTIMATED COST FOR THIS REQUEST IS 112.80 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L4 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:335893 CAPLUS

DOCUMENT NUMBER: 144:390943

TITLE: Preparation of arylpiperazine derivatives as tubulin inhibitors for treatment of proliferation or cancer

INVENTOR(S): Betzemeier, Bodo; Krist, Bernd; McConnell, Darryl; Steurer, Steffen; Impagnatiello, Maria; Weyer-Czernilofsky, Ulrike; Hilberg, Frank; Brueckner, Ralph; Daiimann, Georg; Heckel, Armin; Kley, Joerg; Lehmann-Lintz, Thorsten; Roth, Gerald

PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany

SOURCE: Eur. Pat. Appl., 55 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1645556	A1	20060412	EP 2004-23926	20041007
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRIORITY APPLN. INFO.:			EP 2004-23926	20041007
OTHER SOURCE(S):			CASREACT 144:390943; MARPAT 144:390943	

GI



AB The title arylpiperazine derivs. I [wherein A = mono- or bicyclic aryl; R1 and R2 = independently H, halo, CN, (un)substituted alkyl, alkoxy, etc.; R3 = H, halo, CN, alkyl, or alkoxy; or R2 and R3 = (un)substituted -O-(CH2)p-O- ring; R4 and R5 = independently H or alkyl; R6-R10 =


independently H, halo, NO₂, CN, (un)substituted alkyl, NH₂, alkoxy, etc.; X and Y = independently CH, CF, or N; n and p = independently 1 or 2], or pharmaceutically acceptable salts, derivs., tautomers, or solvates thereof were prepared as tubulin inhibitors for the treatment of proliferative diseases or cancer (no data). For example, 4-amino-3,5-dichlorobenzoic acid was reacted with 1-(3-chlorophenyl)-piperazine in DMF at 50 °C in the presence of TBTU to give II (47 %). The title compds. showed inhibitory activity with IC₅₀ < 10 µM in vitro cytotoxicity assay. Formulations as tablets, coated tablets, capsules, or ampoules were described.

IT 882695-10-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of arylpiperazine derivs. as tubulin inhibitors for treatment of proliferation or cancer)

RN 882695-10-5 CAPLUS

CN Methanone, [4-(3,5-dimethoxyphenyl)-1-piperazinyl](5,6,7,8-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)




OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:979643 CAPLUS
 DOCUMENT NUMBER: 143:266686
 TITLE: Preparation of tetralin derivatives as histamine H3
 receptor antagonists
 INVENTOR(S): Beavers, Lisa Selsam; Gadski, Robert Alan; Hipskind,
 Philip Arthur; Jesudason, Cynthia Darshini; Lindsley,
 Craig William; Lobb, Karen Lynn; Pickard, Richard Todd
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 49 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005082893	A2	20050909	WO 2005-US5491	20050222
WO 2005082893	A3	20060420		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1720861	A2	20061115	EP 2005-723430	20050222
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU			
US 20070155754	A1	20070705	US 2006-598262	20060823
PRIORITY APPLN. INFO.:			US 2004-547758P	P 20040225
			WO 2005-US5491	W 20050222

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): CASREACT 143:266686; MARPAT 143:266686
 GI




I



II


- AB Tetralins of formula I [R1 = CH2NR3R4, CONR3R4, N-methylpiperazinocarbonyl; R2 = H, NH-alkyl, NR3R4, NH-cycloalkyl, N-methylpiperazino, piperidino, pyrrolidino, etc.; R3 = H, alkyl; R4 = alkyl, phenylalkylene; R3R4 = alkylene, etc.] are prepared which have histamine-H3 receptor antagonist activity. The invention discloses pharmaceutical compns. comprising compds. of formula I as well as methods of using them to treat obesity and other histamine H3 receptor-related diseases. Thus, II was prepared and had Ki value of 1.5 nM against GTP γ [35S].
- IT 863925-32-0P 863925-33-1P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of tetralin derivs. as histamine H3 receptor antagonists)
- RN 863925-32-0 CAPLUS
- CN Methanone, [(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl] (5,6,7,8-tetrahydro-2-naphthalenyl)- (CA INDEX NAME)

Absolute stereochemistry.



- RN 863925-33-1 CAPLUS
- CN Methanone, [(2R)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl] (5,6,7,8-tetrahydro-2-naphthalenyl)- (CA INDEX NAME)


Absolute stereochemistry.



- IT 863925-34-2P 863925-35-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of tetralin derivs. as histamine H3 receptor antagonists)
- RN 863925-34-2 CAPLUS
- CN Pyrrolidine, 2-[(1-pyrrolidinylmethyl)-1-[(5,6,7,8-tetrahydro-2-naphthalenyl)methyl]-, (2S)- (9CI) (CA INDEX NAME)

10/513699


Absolute stereochemistry.



RN 863925-35-3 CAPLUS

CN Pyrrolidine, 2-(1-pyrrolidinylmethyl)-1-[(5,6,7,8-tetrahydro-2-naphthalenyl)methyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT:	1	THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT:	3	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 20 CAPLUS COPYRIGHT 2009 ACS ON STN

ACCESSION NUMBER: 2004:354923 CAPLUS

DOCUMENT NUMBER: 140:375196

TITLE: Preparation of substituted piperazines,
[1,4]diazepines, and 2,5-diazabicyclo[2.2.1]heptanes
as histamine H1 and/or H3 antagonists or histamine H3
reverse antagonists

INVENTOR(S): Ancliff, Rachael; Eldred, Colin David; Fogden, Yvonne
C.; Hancock, Ashley Paul; Heightman, Thomas Daniel;
Hobbs, Heather; Hodgson, Simon Teanby; Lindon, Matthew
J.; Wilson, David Matthew

PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 140 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004035556	A1	20040429	WO 2003-EP11423	20031014
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2502249	A1	20040429	CA 2003-2502249	20031014
AU 2003280380	A1	20040504	AU 2003-280380	20031014
BR 2003015283	A	20050830	BR 2003-15283	20031014
EP 1567511	A1	20050831	EP 2003-772221	20031014
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1726201	A	20060125	CN 2003-80106014	20031014
CN 100400523	C	20080709		
JP 2006508935	T	20060316	JP 2004-544241	20031014
NZ 539446	A	20061130	NZ 2003-539446	20031014
CN 101070309	A	20071114	CN 2006-10108610	20031014
NZ 549963	A	20080328	NZ 2003-549963	20031014
RU 2328494	C2	20080710	RU 2005-110061	20031014
IN 2005KN00566	A	20060224	IN 2005-KN566	20050404
NO 2005001689	A	20050707	NO 2005-1689	20050405
ZA 2005002873	A	20060726	ZA 2005-2873	20050408
US 20060025404	A1	20060202	US 2005-531758	20050414
US 7615550	B2	20091110		
MX 2005004078	A	20050608	MX 2005-4078	20050415
ZA 2006003604	A	20070425	ZA 2006-3604	20060505
IN 2006KN02281	A	20070525	IN 2006-KN2281	20060810
JP 2007016041	A	20070125	JP 2006-231163	20060828
PRIORITY APPLN. INFO.:			GB 2002-24084	A 20021016
			CN 2003-80106014	A3 20031014
			JP 2004-544241	A3 20031014

10/513699

2,5-diazabicyclo[2.2.1]heptanes as histamine H1 and/or H3 antagonists
or histamine H3 reverse antagonists)


RN 684244-55-1 CAPLUS

CN Methanone, [4-[4-[3-(1-piperidinyl)propoxy]phenyl]-1-piperazinyl] (5,6,7,8-tetrahydro-2-naphthalenyl)- (CA INDEX NAME)



RN 684244-76-6 CAPLUS

CN Methanone, [4-[4-[3-(5-ethyl-2-methyl-1-piperidinyl)propoxy]phenyl]-1-piperazinyl] (5,6,7,8-tetrahydro-2-naphthalenyl)- (CA INDEX NAME)




RN 684244-95-9 CAPLUS

CN Methanone, [4-[4-[3-(2-methyl-1-piperidinyl)propoxy]phenyl]-1-piperazinyl] (5,6,7,8-tetrahydro-2-naphthalenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 684244-94-8

CMF C30 H41 N3 O2



10/513699

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 684245-17-8 CAPLUS
CN Methanone, [4-[4-[3-(hexahydro-1(2H)-azocinyl)propoxy]phenyl]-1-piperazinyl](5,6,7,8-tetrahydro-2-naphthalenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 684245-16-7
CMF C31 H43 N3 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 684245-35-0 CAPLUS
CN Methanone, [4-[4-[3-(cyclopentylmethylamino)propoxy]phenyl]-1-piperazinyl](5,6,7,8-tetrahydro-2-naphthalenyl)- (CA INDEX NAME)



10/513699

RN 684245-53-2 CAPLUS

CN Methanone, [4-[4-[3-(3-methyl-1-piperidinyl)propoxy]phenyl]-1-piperazinyl](5,6,7,8-tetrahydro-2-naphthalenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS
RECORD (19 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2004:333695 CAPLUS
 DOCUMENT NUMBER: 140:339199
 TITLE: Preparation of 1,4-disubstituted piperidine derivatives and their use as 11- β HSD1 inhibitors
 INVENTOR(S): Barton, Peter John; Jewsbury, Philip John; Pease, Janet Elizabeth
 PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca UK Limited
 SOURCE: PCT Int. Appl., 144 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004033427	A1	20040422	WO 2003-GB4318	20031007
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2501611	A1	20040422	CA 2003-2501611	20031007
AU 2003269242	A1	20040504	AU 2003-269242	20031007
EP 1556349	A1	20050727	EP 2003-751021	20031007
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003015166	A	20050816	BR 2003-15166	20031007
CN 1723199	A	20060118	CN 2003-80105353	20031007
JP 2006506451	T	20060223	JP 2005-500993	20031007
NO 2005001600	A	20050613	NO 2005-1600	20050330
US 20050256159	A1	20051117	US 2005-529951	20050401
MX 2005003632	A	20050603	MX 2005-3632	20050405
ZA 2005002752	A	20060222	ZA 2005-2752	20050405
PRIORITY APPLN. INFO.:			GB 2002-23573	A 20021011
			GB 2003-10446	A 20030507
			WO 2003-GB4318	W 20031007

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 140:339199

GI



AB The title compds. [I; A = carbocyclyl, heterocyclyl; R1 = halo, NO2, CN, OH, etc.; n = 0-5; X = a bond, CO, SO2, CONR11, CSNR11, C(O)O, C(:NR11), CH2 (wherein R11 = H, alkyl, carbocyclyl, heterocyclyl); Y = H, alkyl, alkenyl, carbocyclyl, etc.; R12 = OH, Me, Et. Pr; m, q = 0-1], useful in the manufacture of a medicament for treating diabetes, obesity, hyperlipidemia, etc., were prepared Thus, reacting (4-chlorophenyl)(4-piperidyl)methanone.HCl with 4-fluorobenzoyl chloride in the presence of Et3N in DCM afforded 29% 1-(4-fluorobenzoyl)-4-(4-chlorobenzoyl)piperidine. The compds. I typically show an IC50 < 10 µM against 11βHSD1. The pharmaceutical composition comprising the compound I is claimed.


IT 681130-55-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1,4-disubstituted piperidine derivs. and their use as 11-βHSD1 inhibitors)

RN 681130-55-2 CAPLUS

CN Piperidine, 4-(4-fluorobenzoyl)-1-[(5,6,7,8-tetrahydro-1-naphthalenyl)carbonyl]- (9CI) (CA INDEX NAME)




OS.CITING REF COUNT: 19 THERE ARE 19 CAPLUS RECORDS THAT CITE THIS RECORD (29 CITINGS)

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2003:696782 CAPLUS
 DOCUMENT NUMBER: 139:230625
 TITLE: Preparation of bipiperidiny and related compounds as
 acetyl CoA carboxylase inhibitors useful against
 metabolic syndrome and other disorders
 INVENTOR(S): Perry, David Austen; Harwood, Harold James, Jr.
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: PCT Int. Appl., 181 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003072197	A1	20030904	WO 2003-IB573	20030217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003248354	A1	20030909	AU 2003-248354	20030217
EP 1478437	A1	20041124	EP 2003-742882	20030217
EP 1478437	B1	20050831		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1642599	A	20050720	CN 2003-806990	20030217
AT 303178	T	20050915	AT 2003-742882	20030217
ES 2246481	T3	20060216	ES 2003-742882	20030217
NZ 534582	A	20060331	NZ 2003-534582	20030217
US 20030187254	A1	20031002	US 2003-370844	20030220
US 6979741	B2	20051227		
IN 2004DN02289	A	20070302	IN 2004-DN2289	20040806
ZA 2004006332	A	20050928	ZA 2004-6332	20040810
NO 2004004034	A	20041124	NO 2004-4034	20040924
PRIORITY APPLN. INFO.:			US 2002-365358P	P 20020227
			WO 2003-IB573	W 20030217
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S):		MARPAT 139:230625		
GI				



- AB** Acetyl CoA carboxylase (ACC) inhibitors (shown as I; variables defined below; most examples include the bipiperidinyl ring system, e.g. (anthracen-9-yl)((3R)-3-(morpholine-4-carbonyl)[1,4']bipiperidinyl-1'-yl)methanone), pharmaceutical compns. containing such compds. and the use of such compds. to treat for example, Metabolic Syndrome, atherosclerosis, diabetes and obesity are disclosed. None of pharmacol. activity, therapeutic uses and methods of preparation is claimed and pharmacol. data are not included. More than 200 example preps. and/or characterization data are included for I and intermediates. For I: A-B is N-CH or CH-N; K is (CH₂)_r (r = 2-4); m and n = 1-3 when A-B is N-CH or 2 or 3 when A-B is CH-N; the dashed line = the presence of an optional double bond; D is carbonyl or sulfonyl. E is either (a) a bicyclic ring consisting of two fused fully unsatd. 5-7 membered rings, taken independently, each of said rings optionally having 1-4 heteroatoms = O, S and N; or (b) a tricyclic ring consisting of two fused fully unsatd. 5-7 membered rings, taken independently, each of said rings optionally having 1-4 heteroatoms = O, S and N, said two fused rings fused to a 3rd partially saturated, fully unsatd. or fully saturated 5-7 membered ring, said 3rd ring optionally having 1-4 heteroatoms = O, S and N. Or (c) a tetracyclic ring comprising a bicyclic ring consisting of two fused fully unsatd. 5-7 membered rings, taken independently, each of said rings optionally having 1-4 heteroatoms = O, S and N, said bicyclic ring fused to two fully saturated, partially saturated or fully unsatd. 5-7 membered monocyclic rings taken independently, each of said rings optionally having 1-4 heteroatoms = O, S and N or said bicyclic ring fused to a 2nd bicyclic ring consisting of two fused fully saturated, partially saturated or fully unsatd. 5-7 membered rings, taken independently, each of said rings optionally having 1-4 heteroatoms = O, S and N; or (d) a teraryl ring comprising a fully unsatd. 5-7 membered ring, said ring optionally having 1-4 heteroatoms = O, S and N, and said ring disubstituted independently with a fully unsatd. 5-7 membered ring to form a teraryl nonfused ring system, each of said substituent rings optionally having 1-4 heteroatoms = O, S and N. G is carbonyl, sulfonyl or CR₇R₈ (R₇ and R₈ = H, (C1-C6)alkyl, (C2-C6)alkenyl or (C2-C6)alkynyl or a 5-7 membered partially saturated, fully saturated or fully unsatd. ring optionally having one heteroatom = O, S and N); J is OR₁, NR₂R₃ or CR₄R₅R₆; addnl. details including provisos are given in the claims.
- IT** 591781-07-6P, 1'-((1,2,3,4-Tetrahydroanthracen-9-ylcarbonyl)[1,4']bipiperidinyl-3-carboxylic acid diethylamide


10/513699

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of bipiperidinyl and related compds. as acetyl CoA carboxylase inhibitors useful against metabolic syndrome and other disorders)

RN 591781-07-6 CAPLUS

CN [1,4'-Bipiperidine]-3-carboxamide,
N,N-diethyl-1'-[(1,2,3,4-tetrahydro-9-anthracenyl)carbonyl]- (CA INDEX NAME)



OS.CITING REF COUNT:	16	THERE ARE 16 CAPLUS RECORDS THAT CITE THIS RECORD (30 CITINGS)
REFERENCE COUNT:	2	THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:91070 CAPLUS

DOCUMENT NUMBER: 132:166198

TITLE: Synthesis and platelet aggregation inhibitory activity of 6- [(4-substituted-piperazinyl)phenyl]-5-methyl-4,5-dihydro-3(2H)pyridazinones

AUTHOR(S): Wu, Qiuye; Ni, Jin; Jiang, Yuanying; Liu, Chaomei; Wu, Bo; Zhang, Guangming; Yao, Jiayong


CORPORATE SOURCE: Faculty of Pharmacy, Second Military Medical University, Shanghai, 200433, Peop. Rep. China
Zhongguo Yaowu Huaxue Zazhi (1999), 9(4), 259-263
CODEN: ZYHZEJ; ISSN: 1005-0108

PUBLISHER: Zhongguo Yaowu Huaxue Zazhi Bianjibu

DOCUMENT TYPE: Journal

LANGUAGE: Chinese

GI



AB Title compds. I (R = CH₃, CH₃CH₂, CH₃(CH₂)₃, (CH₃)₂CHCH₂CH₂, CH₃(CH₂)₇, CH₃(CH₂)₁₁, CH₃(CH₂)₁₅, C₆H₅CH₂, 4-ClC₆H₄CH₂, 2-ClC₆H₄CH₂, 3-ClC₆H₄CH₂, 4-CH₃C₆H₄CH₂, CH₃OCOCH₂, 4-CH₃CH₂OCO-C₆H₄CH₂) were prepared from N-acetylaniline via acylation, hydrolysis, cyclization and substitution. The results of preliminary pharmacol. tests showed that all the synthetic compds. had activity against platelet aggregation induced by ADP in vitro in rabbits.


IT 259140-66-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(synthesis and platelet aggregation inhibitory activity of 6-methyl-6-piperazinylphenyldihydropyridazinones)

RN 259140-66-4 CAPLUS

CN 3(2H)-Pyridazinone, 4,5-dihydro-5-methyl-6-[4-[4-[(5,6,7,8-tetrahydro-2-naphthalenyl)methyl]-1-piperazinyl]phenyl]- (CA INDEX NAME)




10/513699


<12/04/2007>

Erich Leese

L4 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2000:62206 CAPLUS
 DOCUMENT NUMBER: 132:207835
 TITLE: Regioselective aminomethylations of bicyclic phenols
 AUTHOR(S): Lange, Jos; Hoogeveen, Sonja; Veerman, Willem; Wals, Henri
 CORPORATE SOURCE: Medicinal Chemistry Department, Solvay Pharmaceuticals
 SOURCE: Research Laboratories, Weesp, 1380 DA, Neth.
 Heterocycles (2000), 53(1), 197-204
 CODEN: HTCYAM; ISSN: 0385-5414
 PUBLISHER: Japan Institute of Heterocyclic Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 132:207835
 AB The regioselectivity in the aminomethylation, Mannich reaction, of bicyclic phenols was studied. Highly regioselective Mannich reactions enable easy synthetic access to novel bicyclic [(dialkylamino)methyl]phenols under very mild reaction conditions.
 IT 260394-47-6P 260394-48-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (regioselective aminomethylation of bicyclic phenols)
 RN 260394-47-6 CAPLUS
 CN 2-Naphthalenol, 5,6,7,8-tetrahydro-3-[(4-methyl-1-piperazinyl)methyl]-
 (CA INDEX NAME)



RN 260394-48-7 CAPLUS
 CN 2-Naphthalenol, 5,6,7,8-tetrahydro-1-[(4-methyl-1-piperazinyl)methyl]-
 (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
 (2 CITINGS)
 REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS

10/513699


RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

<12/04/2007>


Erich Leese

L4 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1999:729780 CAPLUS
 DOCUMENT NUMBER: 132:222471
 TITLE: Synthesis and platelet aggregation activity of 6-[4-substituted-piperazinyl]phenyl]-4,5-dihydro-3(2H)-pyridazinones
 AUTHOR(S): Wu, Qiuye; Zhang, Guangming; Liao, Hongli; Liu, Chaomei
 CORPORATE SOURCE: Faculty of Pharmacy, Second Military Medical Univ., Shanghai, 200433, Peop. Rep. China
 SOURCE: Zhongguo Yaowu Huaxue Zazhi (1999), 9(3), 172-175, 185
 CODEN: ZYHZEJ; ISSN: 1005-0108
 PUBLISHER: Zhongguo Yaowu Huaxue Zazhi Bianjibu
 DOCUMENT TYPE: Journal
 LANGUAGE: Chinese
 GI



- AB Eighteen title compds. I (R = CH₃, CH₃CH₂, CH₃(CH₂)₃, (CH₃)₂CHCH₂CH₂, CH₃(CH₂)₇, CH₃(CH₂)₁₁, CH₃(CH₂)₁₂, CH₃(CH₂)₁₅, C₆H₅CH₂, 4-C₁C₆H₄CH₂, 3-C₁C₆H₄CH₂, 2-C₁C₆H₄CH₂, 4-CH₃C₆H₄CH₂, NCCH₂CH₂, CH₃COCH₂, 4-CH₃CH₂OCOC₆H₄CH₂) were prepared and showed activity against platelet aggregation induced by ADP in vitro in rabbits as antithrombotic drugs. The title compound 6-[(4-n-Octylpiperazin-1-yl)phenyl]-4,5-dihydro-3(2H)-pyridazinone was the most potent.
- IT 260979-38-2P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (synthesis and platelet aggregation activity of substituted piperazinylphenyldihydropyridazinones)
- RN 260979-38-2 CAPLUS
- CN 3(2H)-Pyridazinone, 4,5-dihydro-6-[4-[4-[(5,6,7,8-tetrahydro-2-naphthalenyl)methyl]-1-piperazinyl]phenyl]- (CA INDEX NAME)




L4 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1999:511159 CAPLUS
 DOCUMENT NUMBER: 131:157709
 TITLE: Preparation of bicyclic pyridine and pyrimidine derivatives as neuropeptide Y receptor antagonists
 INVENTOR(S): Norman, Mark H.; Chen, Ning; Han, Nianhe; Liu, Longbin; Hurt, Clarence R.; Fotsch, Christopher H.; Jenkins, Tracy J.; Moreno, Ofir A.
 PATENT ASSIGNEE(S): Amgen Inc., USA
 SOURCE: PCT Int. Appl., 469 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9940091	A1	19990812	WO 1999-US2500	19990205
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6187777	B1	20010213	US 1999-246775	19990204
CA 2319275	A1	19990812	CA 1999-2319275	19990205
CA 2319275	C	20071016		
AU 9926590	A	19990823	AU 1999-26590	19990205
AU 747920	B2	20020530		
EP 1054887	A1	20001129	EP 1999-906756	19990205
EP 1054887	B1	20060412		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
JP 2003502272	T	20030121	JP 2000-530520	19990205
AT 323088	T	20060415	AT 1999-906756	19990205
ES 2257851	T3	20060801	ES 1999-906756	19990205
ZA 9900967	A	19990806	ZA 1999-967	19990208
MX 2000007662	A	20010219	MX 2000-7662	20000804
US 6583154	B1	20030624	US 2000-640263	20000816
PRIORITY APPLN. INFO.:			US 1998-73927P	P 19980206
			US 1998-73981P	P 19980206
			US 1998-93482P	P 19980720
			US 1998-93577P	P 19980720
			US 1999-246775	A 19990204
			WO 1999-US2500	W 19990205

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 131:157709

GI




AB Title compds.[I; R = H, CH₃, (CH₃)₂CH, SCH₃, CH₃CH₂, NH₂, CF₃, NHCOC₆H₅, cyclopropyl, CH₂OH, (CH₃)₂CH₂CH₂, N(CH₃)₂, OCH₃, NHCH₃, NH(CH₂)₄NH₂; R₁ = NH, S, NCH₃, O; R₂ = H, COCH₃, C₆H₅, CH₃, CH₃CH₂; R₃ = NH₂, CH₃, NHC₆H₅, N(CH₂CH₃)₂, (CH₃CH₂)N(CH₂)₃CH₃, (CH₃)N(CH₂)₂NHCH₃, N(CH₃)CH(CH₃)CH(Ph)OH, (CH₃CH₂)NCH₂C(CH₃):CH₂, NHCH₂CF₃, NHCH₂CH₂C₆H₅, NH(CH₂)₃OCH₂CH₃, 4-ClC₆H₄, 4-CH₃OC₆H₅, 2-thienyl, 1-pyrrolidinyl, 1-piperidinyl, 4-morpholinyl, 1-piperazinyl, 3-pyridyl; R₄ = C₆H₅, 4-CH₃C₆H₄, 4-ClC₆H₄, (CH₃)₃C, 4-FC₆H₄, 3-HOC₆H₄, 2-pyridyl, cyclohexyl, 2-furyl, 2-FC₆H₄ 2-thienyl, 1-adamantyl, CH₃, 4-CH₃OC₆H₄; X = N, CH; etc.], pharmaceutical acceptable salts, ester, solvate, and N-oxide are prepared and tested as neuropeptide Y receptor antagonists in the modulation of feeding behavior, obesity, diabetes, cancer, inflammatory disorders, depression, stress related disorders, Alzheimer's disease and other disease conditions. Thus, the title compound I (R = CH₃; R₁ = NH; X = N; R₂ = H; R₃ = N(CH₂CH₃)₂; R₄ = C₆H₅) was prepared

IT 237436-39-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of pyrrolopyridine and pyrrolopyrimidine derivs. as neuropeptide Y receptor antagonists)

RN 237436-39-4 CAPLUS

CN Pyrrolidine, 1-[1-(5,6,7,8-tetrahydro-2-naphthalenyl)ethenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 25 THERE ARE 25 CAPLUS RECORDS THAT CITE THIS RECORD (29 CITINGS)

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1999:495272 CAPLUS

DOCUMENT NUMBER: 131:130011

TITLE: Preparation of N-acyl-2-aminoacetamides and cyclization products thereof.

INVENTOR(S): Hulme, Christopher; Morton, George C.; Salvino, Joseph M.; Labaudiniere, Richard F.; Mason, Helen J.; Morrisette, Matthew M.; Ma, Liang; Cherrier, Marie-Pierre

PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Pharmaceuticals Inc., USA

SOURCE: PCT Int. Appl., 156 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9938844	A1	19990805	WO 1999-US1923	19990129
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2318601	A1	19990805	CA 1999-2318601	19990129
AU 9924821	A	19990816	AU 1999-24821	19990129
AU 747987	B2	20020530		
ZA 9900729	A	20000110	ZA 1999-729	19990129
EP 1051397	A1	20001115	EP 1999-904421	19990129
EP 1051397	B1	20081231		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY				
BR 9908207	A	20001128	BR 1999-8207	19990129
JP 2002501944	T	20020122	JP 2000-530081	19990129
HU 2001001329	A2	20020328	HU 2001-1329	19990129
HU 2001001329	A3	20020729		
CN 1173946	C	20041103	CN 1999-802503	19990129
AP 1462	A	20050930	AP 2000-1864	19990129
W: GH, GM, KE, LS, MW, SD, SZ, UG, ZW				
IL 137571	A	20061210	IL 1999-137571	19990129
AT 419233	T	20090115	AT 1999-904421	19990129
US 6492553	B1	20021210	US 1999-368213	19990804
NO 2000003792	A	20000927	NO 2000-3792	20000724
NO 324067	B1	20070806		
MX 2000007555	A	20010219	MX 2000-7555	20000801
BG 104724	A	20010330	BG 2000-104724	20000829
BG 65057	B1	20070131		

PRIORITY APPLN. INFO.:		
	US 1998-73007P	A2 19980129
	US 1998-98404P	A2 19980831
	US 1998-98708P	A2 19980901
	US 1998-101056P	A2 19980918
	WO 1999-US1923	W 19990129

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OTHER SOURCE(S): MARPAT 131:130011

AB RaRbNCRcRcbRd Ra = RaaCO; Dd = CONHRda; Raa, Rb, Rca, Rcb = H, (substituted) alipharyl, aryl; Rda = (substituted) alipharyl, aryl; with provisos were prepared by reaction of RcaCORcb with RbNH₂, RaCO₂H, and NCRda. Title compds. may be prepared on a isocyanide resin and deprotected/cyclized to give 1,4-benzodiazepine-2,5-diones, diketopiperazines, ketopiperazines, lactams, 1,4-benzodiazapines, and dihydroquinoxalinones.

IT 234781-39-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of N-acyl-2-aminoacetamides and cyclization products thereof)

RN 234781-39-6 CAPLUS

CN 2-Piperazinepentanoic acid, 3-oxo-1-[(5,6,7,8-tetrahydro-2-naphthalenyl)carbonyl]-, methyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1999:172595 CAPLUS

DOCUMENT NUMBER: 130:223167

TITLE: Preparation of piperidinylpyrrolidins as modulators of chemokine receptor activity

INVENTOR(S): Budhu, Richard J.; Hale, Jeffrey J.; Holson, Edward; Lynch, Christopher; Maccoss, Malcolm; Mills, Sander G.; Berk, Scott C.; Willoughby, Christopher A.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 262 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1





PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9909984	A1	19990304	WO 1998-US17755	19980827
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2298813	A1	19990304	CA 1998-2298813	19980827
AU 9892067	A	19990316	AU 1998-92067	19980827
EP 1009405	A1	20000621	EP 1998-944548	19980827
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
US 6166037	A	20001226	US 1998-141227	19980827
JP 2001526178	T	20011218	JP 2000-507374	19980827
PRIORITY APPLN. INFO.:			US 1997-57743P	P 19970828
			GB 1998-1009	A 19980116
			WO 1998-US17755	W 19980827

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 130:223167

GI



AB Title modulators [I; R1 = CH2Ph, SO2Ph, CONHPh, H, CPh, (CH2)3Ph, 1-fluorencarbonyl, etc.; R = OH, H, Ph, CF3, CH2Ph, etc.; n = 0-2; S = S, C; R2 = benzo[d]azepin-3-yl, 4-phenyl-perhydroazepin-1-yl, etc.], pharmaceutically acceptable salts thereof, individual diastereomers, and enantiomers thereof are prepared as modulators of chemokine receptor activity. 21X19 combinatorial library was mentioned using com. available 4-sulfamylbenzoyl polystyrene resin supported subunits (21 pools) of trifluoromethylsulfonyl chloride, arylsulfonyl(carbonyl) chlorides, and heterocyclic sulfonyl(carbonyl) chlorides. Thus, compound II was prepared from Me (Z)-cinnamate and N-(methoxymethyl)-N-(trimethylsilylmethyl)benzylamine via seven steps.


IT 221141-11-3P 221157-12-6P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of piperidinylnpyrrolidins as modulators of chemokine receptor activity)

RN 221141-11-3 CAPLUS

CN Methanone, [(3R,4S)-3-phenyl-4-[(4-phenyl-1-piperidinyl)methyl]-1-pyrrolidinyl](5,6,7,8-tetrahydro-1-naphthalenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.


10/513699



RN 221157-12-6 CAPLUS

CN Methanone, [(3R,4R)-3-phenyl-4-[(4-phenyl-1-piperidinyl)methyl]-1-pyrrolidinyl](5,6,7,8-tetrahydro-1-naphthalenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 34 THERE ARE 34 CAPLUS RECORDS THAT CITE THIS RECORD (34 CITINGS)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:220858 CAPLUS

DOCUMENT NUMBER: 128:270614

ORIGINAL REFERENCE NO.: 128:53569a,53572a

TITLE: Preparation of acylpiperazines and related compounds as inhibitors of farnesyl-protein transferase.

INVENTOR(S): Graham, Samuel L.; Williams, Theresa M.

PATENT ASSIGNEE(S): Merck and Co., Inc., USA

SOURCE: U.S., 50 pp., Cont.-in-part of U.S. Ser. No. 237,586, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5736539	A	19980407	US 1995-549829	19951116
WO 9500497	A1	19950105	WO 1994-US5634	19940519
W: AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KG, KR, KZ, LK, LV, MD, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, US, UZ RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG ZA 9404326 A 19951214 ZA 1994-4326 19940617 PRIORITY APPLN. INFO.: US 1993-80028 B2 19930618 US 1994-237586 B2 19940511 WO 1994-US5634 W 19940519				

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 128:270614

GI



AB Title compds. e.g., [I; X = O, H2; m = 1, 2; n = 0, 1; t = 1, 4; R, R1 = H, alkyl, aralkyl; R2-R5 = H, (substituted) alkyl, alkenyl, alkynyl, aryl, heterocyclyl, acyl; Y = (substituted) aryl, heterocyclyl], were prepared. Thus, 1-[2(R)-amino-3-mercaptopropyl]-2(S)-[2-(3-pyridylmethoxy)ethyl]-4-(1-naphthoyl)piperazine trihydrochloride (preparation given) inhibited RAS farnesylation with IC50 = 1 nM.

IT 169449-54-1 1099473-75-2

RL: PRPH (Prophetic)


(Preparation of acylpiperazines and related compounds as inhibitors of farnesyl-protein transferase.)

RN 169449-54-1 CAPLUS

CN 1-Piperazinepropanethiol, β -amino-2-(2-methoxyethyl)-4-[(5,6,7,8-tetrahydro-1-naphthalenyl)carbonyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

10/513699


Absolute stereochemistry.



RN 1099473-75-2 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



IT 169449-55-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of acylpiperazines and related compds. as inhibitors of farnesyl-protein transferase)

RN 169449-55-2 CAPLUS

CN 1-Piperazinepropanethiol, β -amino-2-(2-methoxyethyl)-4-[(5,6,7,8-tetrahydro-1-naphthalenyl)carbonyl]-, [S-(R*,S*)]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 169449-54-1


CMF C21 H33 N3 O2 S

Absolute stereochemistry.

<12/04/2007>

Erich Leese

10/513699



CM 2

CRN 76-05-1

CMF C2 H F3 O2



OS.CITING REF COUNT: 5

THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
(5 CITINGS)

REFERENCE COUNT: 24

THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1996:70133 CAPLUS

DOCUMENT NUMBER: 124:164423

ORIGINAL REFERENCE NO.: 124:30167a,30170a

TITLE: Synthesis and antimalarial activity of Mannich bases of N-tetrahydronaphthol-substituted 9-amino acridines
 AUTHOR(S): Cao, Shouhai; Li, Fulin
 CORPORATE SOURCE: Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences, Beijing, 100071, Peop. Rep. China


SOURCE: Zhongguo Yiyao Gongye Zazhi (1995), 26(7), 292-4
 CODEN: ZYGZEA; ISSN: 1001-8255

PUBLISHER: Zhongguo Yiyao Gongye Zazhi Bianjibu

DOCUMENT TYPE: Journal

LANGUAGE: Chinese

GI



AB Nine Mannich bases of N-tetrahydronaphthol-substituted 9-amino acridines (I; R = Me, Et, Pr, iso-Pr, Bu, iso-Bu, sec-Bu, pentyl, isopentyl) were synthesized by using α -naphthol and 2-methoxy-6,9-dichloroacridine as starting materials. Preliminary screening showed that the suppressive activity of I (R = Bu, iso-Bu, sec-Bu) against *P. berghei* was equivalent to that of chloroquine and all the others were inferior to chloroquine.

IT 173739-07-6P 173739-08-7P 173739-09-8P

173739-10-1P 173739-11-2P 173739-12-3P

173739-13-4P 173739-14-5P 173739-15-6P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(synthesis and antimalarial activity of Mannich bases of tetrahydronaphthol-substituted amino acridines)

RN 173739-07-6 CAPLUS


CN 1-Naphthalenol, 4-[(6-chloro-2-methoxy-9-acridinyl)amino]-5,6,7,8-tetrahydro-2-[(4-methyl-1-piperazinyl)methyl]- (CA INDEX NAME)

10/513699




RN 173739-08-7 CAPLUS

CN 1-Naphthalenol, 4-[(6-chloro-2-methoxy-9-acridinyl)amino]-2-[(4-ethyl-1-piperazinyl)methyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 173739-09-8 CAPLUS


CN 1-Naphthalenol, 4-[(6-chloro-2-methoxy-9-acridinyl)amino]-5,6,7,8-tetrahydro-2-[(4-propyl-1-piperazinyl)methyl]- (CA INDEX NAME)



RN 173739-10-1 CAPLUS


10/513699

CN 1-Naphthalenol, 4-[(6-chloro-2-methoxy-9-acridinyl)amino]-5,6,7,8-tetrahydro-2-[[4-(1-methylethyl)-1-piperazinyl)methyl]- (CA INDEX NAME)



RN 173739-11-2 CAPLUS


CN 1-Naphthalenol, 2-[(4-butyl-1-piperazinyl)methyl]-4-[(6-chloro-2-methoxy-9-acridinyl)amino]-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 173739-12-3 CAPLUS


CN 1-Naphthalenol, 4-[(6-chloro-2-methoxy-9-acridinyl)amino]-5,6,7,8-tetrahydro-2-[[4-(2-methylpropyl)-1-piperazinyl)methyl]- (CA INDEX NAME)

10/513699




RN 173739-13-4 CAPLUS

CN 1-Naphthalenol, 4-[(6-chloro-2-methoxy-9-acridinyl)amino]-5,6,7,8-tetrahydro-2-[(4-(1-methylpropyl)-1-piperazinyl)methyl]- (CA INDEX NAME)



RN 173739-14-5 CAPLUS

CN 1-Naphthalenol, 4-[(6-chloro-2-methoxy-9-acridinyl)amino]-5,6,7,8-tetrahydro-2-[(4-pentyl-1-piperazinyl)methyl]- (CA INDEX NAME)




<12/04/2007>

Erich Leese

10/513699

RN 173739-15-6 CAPLUS

CN 1-Naphthalenol, 4-[(6-chloro-2-methoxy-9-acridinyl)amino]-5,6,7,8-tetrahydro-2-[[4-(3-methylbutyl)-1-piperazinyl)methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 2

THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)

L4 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1995:881293 CAPLUS

DOCUMENT NUMBER: 123:286080

ORIGINAL REFERENCE NO.: 123:51271a,51274a

TITLE: Preparation of
 α -(mercaptoalkyl)-1-piperazineethanamines as
 inhibitors of farnesyl-protein transferase
 Graham, Samuel L.; Williams, Theresa M.
 Merck and Co., Inc., USA
 PCT Int. Appl., 156 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9500497	A1	19950105	WO 1994-US5634	19940519
W: AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KG, KR, KZ, LK, LV, MD, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, US, UZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2165176	A1	19950105	CA 1994-2165176	19940519
AU 9470412	A	19950117	AU 1994-70412	19940519
AU 675145	B2	19970123		
EP 703905	A1	19960403	EP 1994-919174	19940519
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 09500109	T	19970107	JP 1994-502810	19940519
ZA 9404326	A	19951214	ZA 1994-4326	19940617
US 5736539	A	19980407	US 1995-549829	19951116
PRIORITY APPLN. INFO.:			US 1993-80028	A 19930618
			US 1994-237586	A 19940511
			WO 1994-US5634	W 19940519

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 123:286080

GI



AB Compds. which inhibit farnesyl-protein transferase (FTase) and the

farnesylation of the oncogene protein Ras were disclosed. More narrowly defined claimed compds. are α -(mercaptomethyl)-1-piperazineethanamines I (Y = Ph, aryl, furanyl, etc.; R1-R4 = H, alkyl, substituent, etc.). The invention is further directed to chemotherapeutic compns. containing the compds. of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.

IT 169449-55-2P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of α -(mercaptoalkyl)-1-piperazineethanamines

farnesyl-protein transferase inhibitors)

RN 169449-55-2 CAPLUS


CN 1-Piperazinepropanethiol, β -amino-2-(2-methoxyethyl)-4-[(5,6,7,8-tetrahydro-1-naphthalenyl)carbonyl]-, [S-(R*,S*)]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 169449-54-1

CMF C21 H33 N3 O2 S

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



OS.CITING REF COUNT: 22 THERE ARE 22 CAPLUS RECORDS THAT CITE THIS RECORD (22 CITINGS)


REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/513699

<12/04/2007>

Erich Leese

L4 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1994:508695 CAPLUS
 DOCUMENT NUMBER: 121:108695
 ORIGINAL REFERENCE NO.: 121:19627a,19630a
 TITLE: Syntheses of Mannich basic compounds of tetrahydronaphthol containing piperazine side chains
 AUTHOR(S): Gao, Shouhai; Li, Fulin
 CORPORATE SOURCE: Inst. Pharmacol. Toxicol., Acad. Mil. Med. Sci., Beijing, 100850, Peop. Rep. China
 SOURCE: Zhongguo Yaowu Huaxue Zazhi (1993), 3(3), 175-8
 CODEN: ZYHZEJ; ISSN: 1005-0108
 DOCUMENT TYPE: Journal
 LANGUAGE: Chinese
 GI



AB Title compds. I (R = Me, Et, Pr, Me₂CH, Bu, iso-Bu, EtCHMe, pentyl, isopentyl) were prepared starting from 1-naphthol. I (R = Bu, EtCHMe, isopentyl) showed antimalarial activity comparable to that of chloroquine.


IT	156893-82-2P	156893-83-3P	156893-84-4P
	156893-85-5P	156893-86-6P	156893-87-7P
	156893-88-8P	156893-89-9P	156893-90-2P
	156893-91-3P	156893-92-4P	156893-93-5P
	156893-94-6P	156893-95-7P	156893-96-8P
	156893-97-9P	156893-98-0P	156893-99-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation and antimalarial activity of)

RN 156893-82-2 CAPLUS


CN 1-Naphthalenol, 4-[(7-chloro-4-quinolinyl)amino]-5,6,7,8-tetrahydro-2-[(4-methyl-1-piperazinyl)methyl]- (CA INDEX NAME)

10/513699




RN 156893-83-3 CAPLUS

CN 1-Naphthalenol, 4-[(7-chloro-4-quinolinyl)amino]-2-[(4-ethyl-1-piperazinyl)methyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 156893-84-4 CAPLUS


CN 1-Naphthalenol, 4-[(7-chloro-4-quinolinyl)amino]-5,6,7,8-tetrahydro-2-[(4-propyl-1-piperazinyl)methyl]- (CA INDEX NAME)



RN 156893-85-5 CAPLUS


10/513699

CN 1-Naphthalenol, 4-[(7-chloro-4-quinoliny)amino]-5,6,7,8-tetrahydro-2-[[4-(1-methylethyl)-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 156893-86-6 CAPLUS


CN 1-Naphthalenol, 2-[(4-butyl-1-piperazinyl)methyl]-4-[(7-chloro-4-quinoliny)amino]-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 156893-87-7 CAPLUS


CN 1-Naphthalenol, 4-[(7-chloro-4-quinoliny)amino]-5,6,7,8-tetrahydro-2-[[4-(2-methylpropyl)-1-piperazinyl]methyl]- (CA INDEX NAME)

10/513699




RN 156893-88-8 CAPLUS

CN 1-Naphthalenol, 4-[(7-chloro-4-quinolinyl)amino]-5,6,7,8-tetrahydro-2-[[4-(1-methylpropyl)-1-piperazinyl)methyl]- (CA INDEX NAME)



RN 156893-89-9 CAPLUS


CN 1-Naphthalenol, 4-[(7-chloro-4-quinolinyl)amino]-5,6,7,8-tetrahydro-2-[(4-pentyl-1-piperazinyl)methyl]- (CA INDEX NAME)



10/513699

RN 156893-90-2 CAPLUS

CN 1-Naphthalenol, 4-[(7-chloro-4-quinolinyl)amino]-5,6,7,8-tetrahydro-2-[[4-(3-methylbutyl)-1-piperazinyl)methyl]- (CA INDEX NAME)




RN 156893-91-3 CAPLUS

CN 1-Naphthalenol, 4-[(7-chloro-4-quinolinyl)amino]-5,6,7,8-tetrahydro-2-[[4-methyl-1-piperazinyl)methyl]-, phosphate (1:3) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 156893-82-2

CMF C25 H29 Cl N4 O



CM 2

CRN 7664-38-2

CMF H3 O4 P


10/513699



RN 156893-92-4 CAPLUS
CN 1-Naphthalenol, 4-[(7-chloro-4-quinoliny)amino]-2-[(4-ethyl-1-piperazinyl)methyl]-5,6,7,8-tetrahydro-, phosphate (1:3) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 156893-83-3
CMF C26 H31 Cl N4 O



CM 2

CRN 7664-38-2
CMF H3 O4 P




RN 156893-93-5 CAPLUS
CN 1-Naphthalenol, 4-[(7-chloro-4-quinoliny)amino]-5,6,7,8-tetrahydro-2-[(4-propyl-1-piperazinyl)methyl]-, phosphate (1:3) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 156893-84-4
CMF C27 H33 Cl N4 O

10/513699



CM 2

CRN 7664-38-2

CMF H3 O4 P




RN 156893-94-6 CAPLUS

CN 1-Naphthalenol, 4-[(7-chloro-4-quinolinyl)amino]-5,6,7,8-tetrahydro-2-[[4-(1-methylethyl)-1-piperazinyl]methyl]-, phosphate (1:3) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 156893-85-5

CMF C27 H33 Cl N4 O



<12/04/2007>

Erich Leese

10/513699

CM 2

CRN 7664-38-2

CMF H3 O4 P




RN 156893-95-7 CAPLUS

CN 1-Naphthalenol, 2-[(4-butyl-1-piperazinyl)methyl]-4-[(7-chloro-4-quinolinyl)amino]-5,6,7,8-tetrahydro-, phosphate (1:3) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 156893-86-6

CMF C28 H35 Cl N4 O



CM 2

CRN 7664-38-2

CMF H3 O4 P



RN 156893-96-8 CAPLUS

CN 1-Naphthalenol, 4-[(7-chloro-4-quinolinyl)amino]-5,6,7,8-tetrahydro-2-[[4-(2-methylpropyl)-1-piperazinyl)methyl]-, phosphate (1:3) (salt) (9CI) (CA INDEX NAME)

<12/04/2007>

Erich Leese


10/513699

INDEX NAME)

CM 1

CRN 156893-87-7

CMF C28 H35 Cl N4 O



CM 2

CRN 7664-38-2

CMF H3 O4 P



RN 156893-97-9 CAPLUS


CN 1-Naphthalenol, 4-[(7-chloro-4-quinolinyl)amino]-5,6,7,8-tetrahydro-2-[[4-(1-methylpropyl)-1-piperazinyl]methyl]-, phosphate (1:3) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 156893-88-8

CMF C28 H35 Cl N4 O

10/513699



CM 2

CRN 7664-38-2

CMF H3 O4 P




RN 156893-98-0 CAPLUS

CN 1-Naphthalenol, 4-[(7-chloro-4-quinolinyl)amino]-5,6,7,8-tetrahydro-2-[(4-pentyl-1-piperazinyl)methyl]-, phosphate (1:3) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 156893-89-9

CMF C29 H37 Cl N4 O



<12/04/2007>

Erich Leese

10/513699

CM 2

CRN 7664-38-2

CMF H3 O4 P




RN 156893-99-1 CAPLUS

CN 1-Naphthalenol, 4-[(7-chloro-4-quinolinyl)amino]-5,6,7,8-tetrahydro-2-[[4-(3-methylbutyl)-1-piperazinyl]methyl]-, phosphate (1:3) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 156893-90-2

CMF C29 H37 Cl N4 O



CM 2

CRN 7664-38-2

CMF H3 O4 P



L4 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1958:40588 CAPLUS

DOCUMENT NUMBER: 52:40588

ORIGINAL REFERENCE NO.: 52:7310h-i, 7311a-i, 7312a-e

TITLE: Oxytocic activity of basic (aminomethyl) derivatives

of phenols and related compounds

AUTHOR(S): Cohen, A.; Hall, R. A.; Heath-Brown, B.; Parkes, M. W.; Rees, A. H.

CORPORATE SOURCE: Roche Prods. Ltd., Welwyn Garden City, UK

SOURCE: British Journal of Pharmacology and Chemotherapy (1957), 12, 194-208

CODEN: BJPCAL; ISSN: 0366-0826

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

AB The appropriate phenol, base, and formalin by the Mannich reaction gave the following 2-naphthols [substituent, b.p./mm. or m.p. of base, other consts. given for base, m.p. of salts (HCl = hydrochloride, T = acid tartrate, M = acid maleate)]: 1-(4-ethylpiperidinomethyl), 113°; 1-(2-methylpiperidinomethyl), 94-6°; 1-(4-methylpiperidinomethyl), 131.5-3.5°; 3-piperidinomethyl-5,6,7,8-tetrahydro (I), 77-8°, HCl, 197-8°; 1-(2,4-dimethylpiperidinomethyl), 71-3.5°; 1-(3-ethoxycarbonylpiperidinomethyl), -, HCl, 100°; 1-(3-hydroxymethylpiperidinomethyl), -, M, 157-8°; 1-(4-ethoxycarbonylpiperidinomethyl), -, HCl, 99-101°; 3-(2-methylpiperidinomethyl)-5,6,7,8-tetrahydro, 120°/3 + 10-5, n₂₀D 1.552, T, 60-70°; 3-(3-ethoxycarbonylpiperidinomethyl)-5,6,7,8-tetrahydro, 180°/0.3, HCl, 100°, T, 75-80°; 1-(3-methylpiperidinomethyl), -, M, 157-8°; 1-(2-methyl-5-ethyl-piperidinomethyl), -, M, 70°; 1-piperidinomethyl-3-ethoxycarbonyl, 106-8°, M, 121-3°; 1-(α -piperidinoethyl), -, T, 125°. The following 4,5-dimethylphenols: 2-(2-methylpiperidinomethyl) (II), -, HCl, 190-2°, M, 134-6°; 2-(3-ethoxycarbonylpiperidinomethyl), 116°/10-4, n₂₀D 1.525; 2-(2,4-dimethylpiperidinomethyl), 147°/0.5, n₂₀D 1.527, HCl, 180-2°; 2-(4-ethylpiperidinomethyl), 28-30°, HCl, 162-4°; 2-(4-methylpiperidinomethyl), 44-6° HCl, 180-2°; 2-(4-ethoxycarbonylpiperidinomethyl), 152°/5 + 10-5, n₂₀D 1.522, HCl, 164-6°; 2-(4-hydroxymethylpiperidinomethyl), 75-6°, HCl, 180-2°; 2-(3-methylpiperidinomethyl), 52-4°, -; 2-(2-methyl-5-ethylpiperidinomethyl), 80-1°, -; d-2-(2-methylpiperidinomethyl), 121°/0.3, n₂₀D 1.534, [α]₂₀D 47.1° (c 0.98, benzene), -; l-isomer, 112°/0.14, n₂₀D 1.534, [α]₂₀D -51.4° (c 1.33, benzene), -; 2-hexamethyleniminomethyl, 52°, HCl, 174°; 2-(N-ethyl-N-isopropylaminomethyl), 90°/0.15, n₂₀D 1.516, HCl, 201°; 2-isopropylaminomethyl, 75°, HCl, 137°; 2-diethylaminomethyl, HCl, 190-2°; 2-morpholinomethyl, 129°/0.4, HCl, 198°; 2-(2-ethylpiperidinomethyl), .apprx. 39°, HCl, 174-6°; 2-(5-ethoxycarbonyl-2-methylpiperidinomethyl), -, HCl, 189°; 2-(3-methylmorpholinomethyl), 59-61°, HCl, 165-6°, M, 162-4°; 2-diallylaminomethyl, 120°/0.1, HCl, 136-7°; 2-dimethylaminomethyl, 80-1°, -; 2-pyrrolidinomethyl, 130°/0.1, n₂₀D 1.538, HCl, 149°. The following phenols: 2-piperidinomethyl-3,5-dimethyl, -, M, 121-2°; 6-piperidinomethyl-2,3-dimethyl, 128-30°/0.5, n₂₀D 1.537, HCl,

220-1.5°; 4-piperidinomethyl-2,5-dimethyl, -, HCl, 226-7°;
 4-piperidinomethyl-2,6-dimethyl, -, M, 135-6°;
 2-piperidinomethyl-4,6-dimethyl, -, M, 90°;
 2-piperidinomethyl-3,4,6-trimethyl, -, HCl, 228-30°;
 2-piperidinomethyl-4-methyl, -, HCl, 198°;
 2-piperidinomethyl-5-methyl, -, HCl, 166-8°;
 2-piperidinomethyl-4-chloro-, -, HCl, 231°;
 2-piperidinomethyl-4-chloro-5-methyl, -, HCl, 207°;
 2-piperidinomethyl-4-ethyl-5-methyl, 120°/0.1, n20D 1.534, HCl, 160-2°; 2-piperidinomethyl-3,4,5-trimethyl, 102-3° HCl, 211°; 2-(2-methylpiperidinomethyl)-4-ethyl-5-methyl, 143°/0.5, n20D 1.532, HCl, 143-5°;
 2-piperidinomethyl-4,5-dimethoxy, 119°/5 + 10-5, HCl, 170-2°; 2-piperidinomethyl-4,5-diethyl, 136-8°/0.1, HCl, 178°; 2-piperidinomethyl-5-methyl-propyl, 132°/0.1, n20D 1.531, -; 2-piperidinomethyl-5-ethyl-4-methyl, 117°/0.1, HCl, 154°; 2-piperidinomethyl-4-propyl, 141°/0.75, n20D 1.528, HCl, 178-80°; 2-(2-methylpiperidinomethyl)-5-ethyl-4-methyl, 126°/0.3, n20D 1.531, -; 2-piperidinomethyl-4-cyclohexyl, 59-60° -; 1-2-(2-methylpiperidinomethyl)-4-ethyl-5-methyl, 126-8°/0.19, n20D 1.530, [α]20D -45.7° (c1.25, benzene), -; d-isomer, 126-8°/0.19, n20D 1.530, [α]20D 44.4° (c 1.31, benzene), -;
 2-piperidinomethyl-4-isopropyl-5-methyl, 122°/0.25, n20D 1.531, -. The following 5-hydroxyindans: 6-piperidinomethyl, 125-6°/0.22, n20D 1.549, HCl, 206-8°, M, 118°;
 6-(2-methylpiperidinomethyl), 35-7°, HCl, 173-5°, M, 152-4°; 6-morpholinomethyl, 41-4°, M, 133°;
 6-(3-methylmorpholinomethyl), 58-60°, HCl, 193-5°, M, 153°; 1-6-(2-methylpiperidinomethyl), 133-4°/0.1, n20D 1.549, [α]20D -47.2° (c 0.68, benzene), M, 147-9° [[α]20D -9.9° (c 1.7, water)]; d-isomer, 136-8°/0.12, n20D 1.549, [α]20D 44.9° (c 1.20, benzene), M, 144-7° [[α]20D 7.0° (c 1.63, H2O)]. The following compds.:
 3-hydroxy-4-(piperidinomethyl)quinoline, m. 95°;
 6-hydroxy-5-(piperidinomethyl)quinoline-HCl, m. 214°; and 3-(β-piperidinoethyl)indole-HCl, m. 222.5-4.5°.
 1-Bromo-5,6,7,8-tetrahydro-2-naphthol in a Mannich reaction gave 1-bromo-3-piperidinomethyl-5,6,7,8-tetrahydro-2-naphthol from which Br was eliminated by hydrogenation in HOAc with PdBaSO4 in the presence of KOAc to give I. Also 2-hydroxy-5,6,7,8-tetrahydro-3-naphthoic ester, converted to the piperidide, m. 202-4°, on reduction with LiAlH4 gave I.
 2-Hydroxy-3-naphthopiperidide, prisms, m. 229-30° (MeOH), prepared from 3-ethoxycarbonyl-2-naphthol, on reduction with LiAlH4 gave 3-piperidinomethyl-2-naphthol, m. 159-60°; HCl salt, m. 217.5-19.5°. 2-Bromo-4,5-dimethyl-phenol by a Mannich reaction gave 2-bromo-4,5-dimethyl-6-piperidinomethylphenol, m. 93-5°, debrominated as above to 2-piperidinomethyl-3,4-dimethylphenol, b0.18 120-2°; HCl salt, m. 168-70°. Salicylaldehyde and piperidine hydrogenated with Pd-C catalyst gave 2-piperidinomethylphenol, b0.25 100°, n20D 1.537; HCl salt, m. 160-2°. The Kindler-Willgerodt reaction with 2-benzoyloxy-4,5-dimethylacetophenone gave a substituted phenylacetothiomorpholide, m. 129°, which desulfurized with Raney Ni gave 1-β-[(2-benzyl-oxy-4,5-dimethylphenyl)ethyl]morpholine; picrate, m. 178-8.5°. Hydrogenation of the crude base HCl salt with Pd-C gave 2-(β-morpholinoethyl)-4,5-dimethylphenol-HCl, m. 238-9°.



Similarly, from the phenylacetothiopiperidide was obtained 1- β -[(2-benzoyloxy-4,5-dimethylphenyl)ethyl]piperidine-HCl, m. 180-1°, hydrogenated to 2-(β -piperidinoethyl)-4,5-dimethylphenol-HCl, m. 193-5°. 2-Amino-4,5-dimethylphenol, 1,5-dibromopentane, and K₂CO₃ in boiling BuOH gave 2-piperidino-4,5-dimethylphenol, b0.1 95-7°, n₂₀D 1.539. II was converted to the acetoxy derivative, b0.05 118°, n₂₀D 1.527 and to the benzoyloxy derivative, m. 77-8°, by treating 20 hrs. at 20° with the corresponding chloride in dry pyridine. A mixture of 5-methoxyindan-6-aldehyde and α -pipecoline hydrogenated over Pd-C gave 5-methoxy-6-(2-methylpiperidinomethyl)indan, b0.05 129-31°, n₂₀D 1.543. These compds. were tested for oxytocic activity both in vivo and in vitro and some were found to exceed ergometrine in activity. Highest activity occurred with 2-piperidinomethyl derivs. of phenols, among which maximum potency was conferred by substitution at both the 4 and 5 positions by Me or Et or by linkage of these positions to form an indan derivative. In all series, piperidinomethyl derivs. were more active than those formed with other bases and methylation in the position α to the N atom augmented the activity of both piperidine and morpholine derivs. Among 2-methylpiperidinomethyl phenols, the 1- was more active than the d-form. Acylation or alkylation of the phenolic HO group did not affect activity. The oxytocic activity was specific, the compds. being less effective upon other forms of smooth muscle. Effects upon blood pressure and respiration of a central nature were observed.

IT 1071701-96-6P

RL: SPN (Synthetic preparation); PRP (Properties); PREP (Preparation)
(Oxytocic activity of basic (aminomethyl) derivatives of phenols and related compounds)

RN 1071701-96-6 CAPLUS

CN Butanedioic acid, 2,3-dihydroxy-, 1-[3-[[3-(ethoxycarbonyl)-1-piperidinyl]methyl]-5,6,7,8-tetrahydro-2-naphthalenyl] ester (CA INDEX NAME)




IT 860440-00-2P, 2-Naphthol, 5,6,7,8-tetrahydro-3-piperidinomethyl-
860440-02-4P, 2-Naphthol, 5,6,7,8-tetrahydro-3-piperidinomethyl-,
hydrochloride

RL: PREP (Preparation)
(preparation of)

RN 860440-00-2 CAPLUS


CN 2-Naphthalenol, 5,6,7,8-tetrahydro-3-(1-piperidinylmethyl)- (CA INDEX NAME)

10/513699



RN 860440-02-4 CAPLUS

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-3-(1-piperidinylmethyl)-, hydrochloride
(1:1) (CA INDEX NAME)



● HCl

OS.CITING REF COUNT: 3

THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)

L4 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1957:101470 CAPLUS

DOCUMENT NUMBER: 51:101470

ORIGINAL REFERENCE NO.: 51:18343i,18344a-c

TITLE: Pharmacological research on synthetic uterotonics. II. Substituted N-benzylpiperidines and 3,4-dimethoxybenzylamines

AUTHOR(S): Votava, Z.; Podvalova, I.

CORPORATE SOURCE: Research Inst. Pharmacy and Biochemistry, Prague

SOURCE: Chekhoslovatskaya Fiziologiya (1954), 3, 426-31

CODEN: CHFIAK; ISSN: 0031-9309

DOCUMENT TYPE: Journal


LANGUAGE: English

AB cf. C.A. 50, 8900c. Tests were carried out for pharmacol. properties of the following N-benzylpiperidine derivs.: 3,4-tetramethylene; 2-methoxy; 3-methoxy; 4-methoxy; 2,3-dimethoxy; 2-hydroxy-3-methoxy; 2,4-dimethoxy; 2,5-dimethoxy; 2-hydroxy-5-methoxy; 2,6-dimethoxy; 3,4-dimethoxy; 1-methyl-3,4-dimethoxy; 3,4-methylenedioxy; 3,4-ethylenedioxy; 3-methoxy-4-hydroxy; 3,5-dimethoxy; 2,3,4-trimethoxy; 2,4,5-trimethoxy; 3,4,5-trimethoxy; and 4-hydroxy-3,5-dimethoxy; the following N,N-disubstituted derivs. of 3,4-dimethoxybenzylamine: di-Me; di-Et; di-Pr; di-Bu; and diallyl and the N-(3,4-dimethoxybenzyl) derivs. of: pyrrolidine; piperidine; 2-methylpiperidine; 2,6-dimethylpiperidine; hexamethylenimine; 1-[1-(3,4-dimethoxyphenyl)ethyl]piperidine; and 1-(3-indolylmethyl)-2-methylpiperidine. In all substances, the uterotonic action was studied on in situ expts. in rabbits, the effect on the blood pressure in rabbits, and the toxicity in mice. The substances were always administered intravenously. A regularity was determined between the chemical structure and the uterotonic effect of the substance.

IT 860227-77-6, Piperidine,
1-[(5,6,7,8-tetrahydro-2-naphthyl)methyl]-
(pharmacology of)

RN 860227-77-6 CAPLUS

CN Piperidine, 1-[(5,6,7,8-tetrahydro-2-naphthalenyl)methyl]- (CA INDEX
NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L4 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1956:48646 CAPLUS

DOCUMENT NUMBER: 50:48646

ORIGINAL REFERENCE NO.: 50:9354g-i,9355a-g

TITLE: ar-2-Tetralol derivatives

AUTHOR(S): Hull, Robert L.

SOURCE: Journal of the American Chemical Society (1955), 77, 6376-9

CODEN: JACSAT; ISSN: 0002-7863

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

OTHER SOURCE(S): CASREACT 50:48646


GI For diagram(s), see printed CA Issue.

AB 1-(Piperidinomethyl)-2-naphthol (72.4 g.) in 200 cc. glacial AcOH hydrogenated 20 h. at 60° and 50 lb. over 3.0 g. 5% Pd-C, the mixture filtered into 1 l. ice water, the precipitate filtered off, shaken with 300 cc. Et2O and 300 cc. H2O, the Et2O extract dried, evaporated, and the solid residue recrystd. from ligroine (b. 60-70°) gave 29.4 g. 5-,6-,7,8-tetrahydro-1-methyl-2-naphthol (I), colorless needles, m. 113-14°. I (16.2 g.) and 8.5 g. piperidine in 50 cc. EtOH treated with 8.2 g. 36-8% aqueous CH2O, the mixture allowed to stand overnight, cooled in ice, filtered, and the filter cake washed with cold EtOH yielded 18.1 g. 3-(piperidinomethyl)-derivative of I, m. 57-9°; the mother liquor concentrated gave an addnl. 6.8 g. material, m. 57-9°; anal. sample, m. 60.5-1.5° (from EtOH). I (32.4 g.) in 200 cc. CCl4 treated dropwise during 15 min. with 27.0 g. SO2Cl2, the mixture washed with 300 cc. H2O, 300 cc. 5% aqueous NaHCO3, and 300 cc. H2O, dried, evaporated on the steam bath, the residual oil distilled and the fraction b0.5 90-115°, which solidified, recrystd. from 75 cc. 70% EtOH gave 21.0 g. 3-Cl derivative of I, colorless needles, m. 57-8° (from EtOH). Br (32 g.) in 50 cc. CCl4 added dropwise with stirring to 32.4 g. I in 150 cc. CCl4, the solution stirred 0.5 h., washed with 300 cc. H2O, 300 cc. 5% aqueous NaHCO3, and 500 cc. H2O, dried, evaporated, and the solid residue recrystd. from 70% EtOH gave 36.5 g. 3-Br derivative of I, colorless needles, m. 69-70°. 5,6,7,8-Tetra-hydro-3-Pr 2-naphthol (II) treated with Br in CCl4 yielded 53% 1-Br derivative of II, m. 64.5-5.5° (from 70% EtOH). The appropriate ar-2-tetralol (0.05 mol) in 25 cc. absolute EtOH added to 1.15 g. Na in 20 cc. absolute EtOH, the mixture treated with HOCH2CH(OH)CH2Cl or HOCH2CMe(OH)CH2Cl, refluxed 3 h., filtered, the filtrate evaporated, and the residue recrystd. or distilled gave the corresponding III (R, X, Y, % yield, and m.p. given): H, Me, H, 42, 109-10°; Me, Me, H, 34, 91.5-2.5°; Me, H, H, 70, 80-1°; H, Br, H, 31, 120-1°; H, Br, Br, 42, 104.5-5.5°; H, Me, Br, 29, 85.5-6.5°; H, Me, Cl, 24, 81-2°; Me, Me, Br, 51, 102.5-3.5°; H, H, CH2CH:CH2, 21, 66-7°; H, H, Pr, 47, 88-9°; Me, H, CH2CH:CH2, 44, - (b0.5 175-80°); Me, Br, Br, 23, 81-2°; H, Br, Pr, 51, 86-7°; Me, Br, Pr, 23, 80-1°.

1,3-Dibromo-5,6,7,8-tetrahydro-2-naphthyl acetate (10.4 g.) added to 2.8 g. NaOH in 40 cc. 70% EtOH, the mixture refluxed 1 h., treated with 0.040 mol of the appropriate glycerol monohydrin, refluxed 3 h., evaporated in vacuo at 50°, the gummy residue extracted with 100 cc. hot C6H6, the extract evaporated, and the residue recrystd. gave the III (X and Y = Br). I (34.5 g.) and 20 cc. concentrated H2SO4 heated 0.5 h. on the steam bath, the deep red solution diluted with 150 cc. H2O, cooled in ice, treated with stirring with 14 cc. concentrated HNO3, the mixture heated 10 min. on the steam bath, diluted with an equal volume of H2O, cooled in ice, and the yellow precipitate filtered, washed

with H₂O, and recrystd. from EtOH gave 26.4 g. 3-nitro derivative (IV) of I, yellow needles, m. 118-19°. II nitrated in the same manner yielded 60% 1-nitro derivative (V) of II, yellow needles, m. 104-5° (from EtOH). IV (10.4 g.) in 200 cc. absolute EtOH hydrogenated 10 min. at room temperature and 50 lb. pressure over 0.1 g. PtO₂, the mixture filtered, the filtrate diluted with 4 vols. H₂O, and the precipitate filtered off, dried (8.5 g.), and recrystd. from ligroine gave the 3-amino derivative (VI) of I, m. 144-5°. V hydrogenated in the same manner yielded 71% 1-amino derivative (VII) of II, m. 95-6° (from aqueous EtOH). VI (8.1 g.) and 25 cc. 98% HCO₂H refluxed 1 h., the excess HCO₂H and H₂O distilled off, the residue heated 4 h. at 140-50°, the cooled solid extracted with two 50-cc. portions of Me₃CCH₂CHMe₂, the extract cooled in ice, and the white crystalline deposit (5.7 g.) recrystd. from EtOH gave 5,6,7,8-tetrahydro-9-methylnaphth[2,3]oxazole (VIII), colorless crystals, m. 94-5°. VII gave similarly 60% 6,7,8,9-tetrahydro-4-propylnaphth[1,2]oxazole (IX), colorless oil, b_{0.1} 99-101°. NH₂OH.HCl (1.3 g.) and 3.4 g. VIII added to 0.8 g. NaOH in 25 cc. H₂O and 30 cc. EtOH, the mixture refluxed 0.5 h., diluted with an equal volume of H₂O, cooled in ice, and the cream-colored solid deposit filtered, dried (2.6 g.), and recrystd. from EtOH-C₆H₆ gave the 2-NH₂ derivative of VIII.H₂O, m. 159-60°. IX gave similarly 64% 2-NH₂ derivative of IX, m. 174-5° (from ligroine).

IT 412014-25-6P, Piperidine,
 RL: PREP (Preparation)
 (preparation of)
 RN 412014-25-6 CAPLUS
 CN 2-Naphthalenol, 5,6,7,8-tetrahydro-1-methyl-3-(1-piperidinylmethyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)

L4 ANSWER 19 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1956:40401 CAPLUS

DOCUMENT NUMBER: 50:40401

ORIGINAL REFERENCE NO.: 50:7803c-f

TITLE: Chloromethylation of tetralin

AUTHOR(S): Vanags, G.; Gudriniece, E.

SOURCE: Latvijas PSR Zinatnu Akademijas Vestis (1955), (No. 5 (Whole No. 94)), 119-24

CODEN: LZAVAL; ISSN: 0132-6422

DOCUMENT TYPE: Journal

LANGUAGE: Russian

AB Tetralin (66 mg.), 28 g. (CH₂O)_n, 65 ml. glacial AcOH, 33 g. crystalline H₃PO₄, and 91 ml. concentration HCl at 85-90° stirred 4 hrs. gave 66% 1,2,3,4-tetrahydro-6-chloromethylnaphthalene (I). With excess II, 10% 5,8-bis(chloromethyl)-1,2,3,4-tetrahydronaphthalene was obtained in addition to I. The 6-piperidinomethyl analog (II of I) was prepared by treating I in Et₂O with piperidine at room temperature II decomposed on distillation


Bubbling dry HCl

through II in Et₂O gave II.HCl, very hygroscopic. II picrate, m. 150°. 1-(1,2,3,4-Tetrahydro-6-naphthylmethyl)pyridinium chloride, m. 115°, was prepared (88.5% yield) from 7.2 g. I, 20 ml. absolute Et₂O, and dry pyridine. H₂NC(SR):NH.HCl (R = 1,2,3,4-tetrahydro-6-naphthylmethyl), m. 212°, was prepared (96% yield) by heating 7.2 g. I with 6 g. thiourea. RCO₂H was prepared (42% yield) refluxing crude I with KCN in H₂O, and hydrolyzing the nitrile with aqueous NaOH; the hydrolysis was aided, and formation of resinous products was minimized by adding small amts. of 3% H₂O₂ at intervals. RCONHPh, m. 112°, was obtained by method similar to that described (C.A. 50, 271f).

IT 860227-77-6, Piperidine,
1-[(5,6,7,8-tetrahydro-2-naphthyl)methyl]-
(and derivs.)

RN 860227-77-6 CAPLUS

CN Piperidine, 1-[(5,6,7,8-tetrahydro-2-naphthalenyl)methyl]- (CA INDEX NAME)




IT 857435-57-5P, Pyridinium,
1-[(5,6,7,8-tetrahydro-2-naphthyl)methyl]-, chloride
RL: PREP (Preparation)

(preparation of)


RN 857435-57-5 CAPLUS

CN Pyridinium, 1-[(5,6,7,8-tetrahydro-2-naphthalenyl)methyl]-, chloride (1:1)
(CA INDEX NAME)

10/513699



L4 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1950:10095 CAPLUS
 DOCUMENT NUMBER: 44:10095
 ORIGINAL REFERENCE NO.: 44:1979i,1980a-b
 TITLE: Piperidylmethyl compounds with oxytocic action
 AUTHOR(S): Schindler, O.; Voegtli, W.
 SOURCE: Pharmaceutica Acta Helvetica (1949), 24, 207-16
 CODEN: PAHEAA; ISSN: 0031-6865
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 AB Procedures for preparing the following compds. are given:
 2-(1-piperidylmethyl)-5,6,7,8-tetrahydronaphthalene,
 2-(1-piperidylmethyl)-1-chlorocyclohexane,
 1-(1-piperidylmethyl)cyclohexene, 2-(1-piperidylmethyl)-1-
 chlorocyclopentane, and 1-(1-piperidylmethyl)cyclopentene. These compds.
 appear to have about 0.1 the activity of methylergobasine when tested on
 the uterus of the guinea pig. 22 references.
 IT 860227-77-6, Piperidine,
 1-[(5,6,7,8-tetrahydro-2-naphthyl)methyl]-
 (and derivs.)
 RN 860227-77-6 CAPLUS
 CN Piperidine, 1-[(5,6,7,8-tetrahydro-2-naphthalenyl)methyl]- (CA INDEX
 NAME)



10/513699

=> d his

(FILE 'HOME' ENTERED AT 17:55:20 ON 23 NOV 2009)

FILE 'REGISTRY' ENTERED AT 17:55:27 ON 23 NOV 2009

L1 STRUCTURE UPLOADED

L2 0 S L1 SSS

L3 190 S L1 FULL

FILE 'CAPLUS' ENTERED AT 17:56:37 ON 23 NOV 2009

L4 20 S L3 FULL

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

125.30

311.88

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-16.40

-16.40

STN INTERNATIONAL LOGOFF AT 18:11:52 ON 23 NOV 2009